An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
Researchers sought to determine whether imetelstat would have efficacy in patients with lower risk MDS that is relapsed/refractory to erythropoiesis stimulating agents.
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Researchers sought to determine whether there would be a difference in outcomes for patients with lower-risk MDS with either a 5- or 7-day dosing schedule of azacitidine.
Researchers sought to determine whether an online educational program regarding myelodysplastic syndromes would provide benefits to learners’ understanding of MDS.
Researchers sought to determine whether elevated platelet-to-lymphocyte ratio and plasma C-reactive protein level would help predict prognosis for patients with MDS.
A head-to-head comparison of 7-day and 5-day treatment schedule of azacitidine in patients with higher risk myelodysplastic syndromes revealed trends in overall survival and time to transformation to leukemia.
Researchers sought to identify features related to failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
Researchers sought to determine whether nonablative chemotherapy followed by HLA-mismatched allogeneic T-cell infusion would be safe and effective in older patients with AML or MDS.
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Researchers sought to determine whether detecting MRD with mutational analysis and FCM may aid in predicting disease progression following myeloablative allo-HSCT in patients with MDS.
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.
Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.